Barclays Has Lowered Expectations for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its target price decreased by equities research analysts at Barclays from $16.00 to $14.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 53.07% from the company’s previous close.

CERT has been the subject of several other research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Certara in a research report on Wednesday, October 8th. UBS Group lowered their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Craig Hallum assumed coverage on Certara in a research note on Monday, September 29th. They issued a “buy” rating and a $16.00 price target on the stock. Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Finally, KeyCorp boosted their target price on Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.38.

Certara Trading Down 18.8%

Shares of CERT stock traded down $2.12 during trading hours on Friday, reaching $9.15. The company’s stock had a trading volume of 2,549,557 shares, compared to its average volume of 1,713,118. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara has a one year low of $8.64 and a one year high of $15.69. The stock has a market capitalization of $1.47 billion, a P/E ratio of 184.28 and a beta of 1.44. The firm’s fifty day simple moving average is $11.82 and its 200 day simple moving average is $11.55.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. Certara had a net margin of 1.97% and a return on equity of 5.11%. The business had revenue of $104.62 million for the quarter, compared to analysts’ expectations of $104.53 million. During the same quarter in the previous year, the business posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Equities research analysts expect that Certara will post 0.28 EPS for the current year.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider directly owned 73,979 shares of the company’s stock, valued at $807,850.68. This represents a 40.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.33% of the company’s stock.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Summitry LLC boosted its stake in shares of Certara by 16.1% in the third quarter. Summitry LLC now owns 19,814 shares of the company’s stock worth $242,000 after acquiring an additional 2,749 shares during the period. Public Sector Pension Investment Board grew its stake in Certara by 24.9% during the third quarter. Public Sector Pension Investment Board now owns 469,910 shares of the company’s stock valued at $5,742,000 after acquiring an additional 93,810 shares in the last quarter. Illinois Municipal Retirement Fund increased its holdings in Certara by 10.8% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 60,732 shares of the company’s stock valued at $742,000 after acquiring an additional 5,943 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Certara by 5.5% in the third quarter. Rhumbline Advisers now owns 278,479 shares of the company’s stock worth $3,403,000 after purchasing an additional 14,578 shares during the last quarter. Finally, Prospera Financial Services Inc bought a new position in Certara during the third quarter valued at approximately $288,000. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.